- Home
- STEM vs CRDL Comparison
STEM vs CRDL Comparison
Compare STEM & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEM
- CRDL
- Stock Information
- Founded
- STEM 2009
- CRDL 2017
- Country
- STEM United States
- CRDL Canada
- Employees
- STEM N/A
- CRDL N/A
- Industry
- STEM Computer Software: Prepackaged Software
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STEM Technology
- CRDL Health Care
- Exchange
- STEM Nasdaq
- CRDL Nasdaq
- Market Cap
- STEM 126.2M
- CRDL 126.5M
- IPO Year
- STEM N/A
- CRDL N/A
- Fundamental
- Price
- STEM $14.87
- CRDL $1.31
- Analyst Decision
- STEM Hold
- CRDL Strong Buy
- Analyst Count
- STEM 7
- CRDL 2
- Target Price
- STEM $10.00
- CRDL $9.00
- AVG Volume (30 Days)
- STEM 784.5K
- CRDL 1.2M
- Earning Date
- STEM 08-07-2025
- CRDL 08-26-2025
- Dividend Yield
- STEM N/A
- CRDL N/A
- EPS Growth
- STEM N/A
- CRDL N/A
- EPS
- STEM N/A
- CRDL N/A
- Revenue
- STEM $156,002,000.00
- CRDL N/A
- Revenue This Year
- STEM $5.06
- CRDL N/A
- Revenue Next Year
- STEM $19.03
- CRDL N/A
- P/E Ratio
- STEM N/A
- CRDL N/A
- Revenue Growth
- STEM N/A
- CRDL N/A
- 52 Week Low
- STEM $5.81
- CRDL $0.77
- 52 Week High
- STEM $33.60
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- STEM 58.03
- CRDL 51.92
- Support Level
- STEM $11.14
- CRDL $0.94
- Resistance Level
- STEM $15.35
- CRDL $1.55
- Average True Range (ATR)
- STEM 1.55
- CRDL 0.13
- MACD
- STEM -0.01
- CRDL -0.00
- Stochastic Oscillator
- STEM 51.21
- CRDL 59.74
About STEM Stem Inc.
Stem Inc is a provider of energy storage systems. The company bundles third-party hardware with its proprietary Athena software to provide customers a turnkey solution. Stem sells its solutions to commercial and industrial customers as well as independent power producers and renewable developers. Its solutions help customers maximize renewable energy generation and help build a cleaner and more resilient grid. The Company operates as one operating segment that is focused exclusively on technology services that transform the way energy is distributed and consumed.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.